AstraZeneca PLC (AZN)vsPark Dental Partners, Inc. Common Stock (PARK)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
PARK
Park Dental Partners, Inc. Common Stock
$17.58
-0.40%
HEALTHCARE · Cap: $82.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 23925% more annual revenue ($58.74B vs $244.49M). AZN leads profitability with a 17.4% profit margin vs -0.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PARK
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for PARK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 526.0% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -4.1% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PARK
The strongest argument for PARK centers on EPS Growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PARK
The primary concerns for PARK are Market Cap, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a value stock while PARK is a turnaround play — different risk/reward profiles.
PARK is growing revenue faster at 7.5% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Park Dental Partners, Inc. Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?